Corcept Therapeutics Incorporated (LON:0I3Q)
64.94
-4.72 (-6.77%)
Feb 21, 2025, 4:33 PM BST
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $182.55M USD in the quarter ending September 30, 2024, with 47.69% growth. This brings the company's revenue in the last twelve months to $628.56M, up 39.67% year-over-year. In the year 2023, Corcept Therapeutics had annual revenue of $482.38M with 20.04% growth.
Revenue (ttm)
$628.56M
Revenue Growth
+39.67%
P/S Ratio
n/a
Revenue / Employee
$1.79M
Employees
352
Market Cap
5.27B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Corcept Therapeutics News
- 10 days ago - Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 25 days ago - Big Money Keeps Buying Corcept - FX Empire
- 4 weeks ago - Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm - PRNewsWire
- 4 weeks ago - Corcept Therapeutics Generating Strong Revenue And Profit Growth - Seeking Alpha
- 4 weeks ago - Medical Stock Soars To Highs As Cortisol Screening Grows - Investor's Business Daily
- 7 weeks ago - Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
- 2 months ago - Corcept Therapeutics Inc (CORT) Announces Promising Phase 3 Study Results for Relacorilant - GuruFocus
- 2 months ago - Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - Business Wire